Charles River Laboratories International, Inc. (CRL)
| Market Cap | 9.40B |
| Revenue (ttm) | 3.69B |
| Net Income (ttm) | 443.35M |
| Shares Out | 50.14M |
| EPS (ttm) | 8.34 |
| PE Ratio | 22.48 |
| Forward PE | 15.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 800,554 |
| Open | 183.31 |
| Previous Close | 184.83 |
| Day's Range | 182.02 - 188.08 |
| 52-Week Range | 182.02 - 455.60 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 278.12 (+48.3%) |
| Earnings Date | Nov 1, 2022 |
About CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provi... [Read more...]
Financial Performance
In 2021, CRL's revenue was $3.54 billion, an increase of 21.08% compared to the previous year's $2.92 billion. Earnings were $390.98 million, an increase of 7.32%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 278.12, which is an increase of 48.32% from the latest price.
News
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
Charles River (CRL) to Support Cure AP-4's Clinical Trials
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at September Conferences
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
ALDERLEY PARK, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Cure AP-4 announce a manufacturing collaboration to provide HQ plasmid DNA for Phase I/II gene therapy trials against AP-4 ...
Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River Laboratories Expands Contract Vivarium Space on West Coast
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the addition of five CRADL locations, expanding operations to 27 vivarium facilities in key biohubs.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogene...
MEMPHIS, Tenn.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River is first CDMO in North America to receive EMA approval to commercially produce an allogeneic cell therapy drug product
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories Announces Second-Quarter 2022 Results
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Announces Second-Quarter 2022 Results
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
These 2 Stocks May Be Recession-Proof
While many companies worry about the global economy, Charles River and Thermo Fisher are optimistic.
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Here's Why Investors Should Retain Charles River (CRL) Now
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
WILMINGTON, Mass. & MACCLESFIELD, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech's Alderley...
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine prog...
Charles River (CRL) Prospers Internationally Amid FX Headwind
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and ASC Therapeutics announce expanded relationship to scale manufacturing for a second generation gene therapy for hemophilia A.
Charles River Labs stock slides 6% premarket after company issues profit warning for Q2
Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expected ...
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #conference--Charles River Laboratories to present at June conferences